- Home
- FROG vs MRUS Comparison
FROG vs MRUS Comparison
Compare FROG & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FROG
- MRUS
- Stock Information
- Founded
- FROG 2008
- MRUS 2003
- Country
- FROG United States
- MRUS Netherlands
- Employees
- FROG N/A
- MRUS N/A
- Industry
- FROG Computer Software: Prepackaged Software
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- FROG Technology
- MRUS Health Care
- Exchange
- FROG Nasdaq
- MRUS Nasdaq
- Market Cap
- FROG 3.6B
- MRUS 2.9B
- IPO Year
- FROG 2020
- MRUS 2016
- Fundamental
- Price
- FROG $30.86
- MRUS $41.85
- Analyst Decision
- FROG Strong Buy
- MRUS Strong Buy
- Analyst Count
- FROG 18
- MRUS 12
- Target Price
- FROG $36.29
- MRUS $87.92
- AVG Volume (30 Days)
- FROG 888.1K
- MRUS 637.6K
- Earning Date
- FROG 02-12-2025
- MRUS 10-31-2024
- Dividend Yield
- FROG N/A
- MRUS N/A
- EPS Growth
- FROG N/A
- MRUS N/A
- EPS
- FROG N/A
- MRUS N/A
- Revenue
- FROG $409,670,000.00
- MRUS $35,932,000.00
- Revenue This Year
- FROG $24.37
- MRUS N/A
- Revenue Next Year
- FROG $17.11
- MRUS $57.37
- P/E Ratio
- FROG N/A
- MRUS N/A
- Revenue Growth
- FROG 24.45
- MRUS N/A
- 52 Week Low
- FROG $22.91
- MRUS $26.69
- 52 Week High
- FROG $48.81
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- FROG 50.68
- MRUS 39.11
- Support Level
- FROG $30.11
- MRUS $41.03
- Resistance Level
- FROG $32.38
- MRUS $45.25
- Average True Range (ATR)
- FROG 1.05
- MRUS 2.21
- MACD
- FROG -0.06
- MRUS 0.02
- Stochastic Oscillator
- FROG 49.50
- MRUS 10.15
About FROG JFrog Ltd.
JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from Israel and also has its presence in United States, India and other regions.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.